# The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

> **NCT03182673** · PHASE1 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SHR7390
- **BIOLOGICAL:** SHR-1210
- **DRUG:** SHR3162

## Key facts

- **NCT ID:** NCT03182673
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-24
- **Primary completion:** 2019-06-12
- **Final completion:** 2019-06-12
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Sponsor R \& D Strategy Adjustment
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03182673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03182673, "The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03182673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*